Easily administered screening tool may help identify axial psoriatic arthritis
A study found more than half of Psoriatic arthritis patients have a diagnostic delay of more than two years. This delay increases the risk of irreversible joint damage.In a recent investigation, researchers said, “Dermatologist-centred screening (DCS) questionnaire reduces delay in diagnosis and the time to appropriate therapy.” This Italian study published in Rheumatology identified DCS as...
A study found more than half of Psoriatic arthritis patients have a diagnostic delay of more than two years. This delay increases the risk of irreversible joint damage.
In a recent investigation, researchers said, “Dermatologist-centred screening (DCS) questionnaire reduces delay in diagnosis and the time to appropriate therapy.” This Italian study published in Rheumatology identified DCS as a rapid and easy-to-administer tool that could help in identifying psoriatic patients having early axial psoriatic arthritis.
Dermatologists administered DCS questionnaires to patients aged 18+ with psoriasis diagnosed by a dermatologist to identify those eligible for rheumatological evaluation. They collected data (clinical, laboratory, imaging and genetic) from all referred patients.
Key findings from the study are:
- Out of 365 patients screened, 265 patients met the inclusion criteria.
- One hundred twenty-four patients were eligible for rheumatological referral.
- Diagnosis of axPsA, with/without peripheral PsA (pPsA), was made in 36 patients.
- Twenty-one patients had pPsA without axial involvement.
- One hundred seventy-four patients had Back pain at screening.
- A total of 158 patients, constituting 60%, reported back pain duration longer than three months, and 140, constituting 53%, reported back pain onset before 45 years of age.
- All axPsA patients had active inflammatory and/or structural post-inflammatory changes in the sacroiliac joints and/or spine.
Psoriatic arthritis patients had a longer duration of back pain and higher CRP levels than patients with Pso without PsA.
Researchers determined a DCS tool valuable in identifying and assessing patients with axPsA in a real-life cohort of psoriasis patients in a dermatology clinic. It helped identify a significant number of patients with undiagnosed pPsA.
AbbVie funded the study for medical writing.
Reference:
Michele Maria Luchetti Gentiloni et al. The ATTRACT study: screening for the early identification of axial psoriatic arthritis in a cohort of Italian psoriatic patients, Rheumatology, 2023; kead566, https://doi.org/10.1093/rheumatology/kead566
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd